Darian Fentos

From the Royal Australian College of General Practitioners (05 Aug 2021):

“‘In Australia, severe cases of TTS appear to be more common in women in younger age groups,’ the Therapeutic Goods Administration (TGA) announced in its latest weekly safety report. ‘Nearly half of the TTS cases in women required treatment in intensive care.’”

“According to the TGA, Australian TTS cases that have met the criteria for Tier 1 as defined by the US Centers for Disease Control and Prevention are twice as likely to occur in women than men.”

“‘Five of the six deaths occurred in women aged 34, 48 (two cases), 52 and 72 years old,’ the administration said. ‘The other death was in a 44-year-old man.’”

“The CDC classification for TTS: Tier 1 – clots in an unusual location (such as the brain or abdomen) and a low platelet count with or without antibodies that activate platelets (anti-PF4 antibodies).”

Roll up your sleeve, Australia. Don't worry. Worst case scenario, the TGA will offer its sincerest condolences:

“Sadly, a 34-year-old woman from NSW died yesterday from confirmed TTS following a first dose of the AstraZeneca vaccine. The TGA extends its sincerest condolences to her family and loved ones.”

'Safe and effective'. 'Safe and effective'. Repeat it enough times, you may actually start to believe it.